113 个 · 按相关度排序
Analyze healthcare claims data for real-world evidence (RWE) studies. Use when working with medical/pharmacy claims (837/835), calculating utilization metrics, building patient cohorts, or analyzing treatment patterns. Triggers include claims data, RWE, real-world evidence, 837, 835, medical claims, pharmacy claims, utilization, treatment patterns, HEDIS, healthcare analytics.
中文简介正在准备中。当前显示原文说明。
CVS Health engineering with integrated healthcare delivery across pharmacy, insurance (Aetna), and retail clinics. Triggers: 'CVS style', 'healthcare integration', 'pharmacy systems', 'Aetna', 'MinuteClinic'.
中文简介正在准备中。当前显示原文说明。
Prepare herbal remedies from Hildegard von Bingen's Physica. Covers plant identification, preparation methods (tinctures, poultices, infusions, decoctions), dosage guidance, contraindications, and safety review based on 12th-century medieval pharmacopeia. Use when needing an herbal remedy for a specific ailment using Hildegardian pharmacopeia, seeking guidance on preparation methods and dosage, researching medieval herbal medicine, or integrating Hildegard's plant wisdom into holistic health practice.
中文简介正在准备中。当前显示原文说明。
Audit pharmaceutical regulatory compliance -- inspection readiness, CAPA system effectiveness, change control pipeline, data integrity (ALCOA+), and validation lifecycle tracking..
中文简介正在准备中。当前显示原文说明。
Audit pharmaceutical QC laboratory operations -- OOS/OOT investigations, stability program trending, analytical method validation status, release testing optimization, and specification compliance..
中文简介正在准备中。当前显示原文说明。
Analyze pharmaceutical batch production records for yield optimization, process parameter tuning, deviation trending, and cycle time reduction under cGMP compliance. Triggers: phrases: "optimize batch yield", "analyze batch records", "pharma manufacturing analysis".
中文简介正在准备中。当前显示原文说明。
Drafts an Adverse Event Reporting Policy compliant with 21 CFR 312.32 (IND safety reporting), 21 CFR 314.80 (postmarketing), and ICH E2A, with multi-jurisdictional overlays (EMA, PMDA, Health Canada). Covers seriousness/causality frameworks, expedited reporting timelines, roles, documentation standards, training mandates, and QA mechanisms. Use when drafting or updating an adverse event reporting policy, pharmacovigilance policy, AE/SAE reporting SOP, or safety reporting framework for a pharmaceutical company, CRO, biotech, or clinical research institution.
中文简介正在准备中。当前显示原文说明。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/interaction. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/alleles. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/metabolism. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/visualization. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/annotations. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory src/metainformant/pharmacogenomics/clinical. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
METAINFORMANT rules for directory docs/pharmacogenomics. Use when editing, adding tests, or reviewing code under this path. Read the linked AGENTS.md first; use uv only, write outputs to output/, real implementations.
中文简介正在准备中。当前显示原文说明。
GPCR receptor pharmacology — agonist/antagonist/inverse-agonist/biased-agonist classification, GPCRdb structural data, receptor-ligand binding analysis, antibody-target interface (SAbDab). Use for GPCR drug discovery, biased-agonism analysis, receptor subtype selectivity questions, and orthosteric vs allosteric pocket characterization.
中文简介正在准备中。当前显示原文说明。
Compound-target-disease network construction and analysis for drug repurposing, polypharmacology discovery, and multi-target drug design. Uses STRING, BioGRID, ChEMBL, DGIdb, OMIM, OpenTargets. Use for off-target effect prediction, network-based drug repurposing, and identifying molecules with desired multi-target profile.
中文简介正在准备中。当前显示原文说明。
Assess drug-drug interactions — CYP metabolic interactions (substrate/inhibitor/inducer), transporter (P-gp, BCRP, OATP) effects, pharmacodynamic synergy/antagonism, clinical significance scoring, and management recommendations. Use for polypharmacy review, prescribing decision support, and safety analysis when adding or switching drugs.
中文简介正在准备中。当前显示原文说明。
Pharmacokinetic (PK) analysis of concentration-time data — non-compartmental analysis (NCA) for Cmax, Tmax, AUC (0-t and 0-∞), terminal half-life, clearance (CL), volume of distribution (Vd), MRT, and absolute bioavailability (F). Also one-compartment fitting. Use when you have plasma/serum drug concentrations over time after a dose and need PK parameters, or to compute bioavailability from IV + oral AUCs. NOT for ADMET property prediction from structure (use tooluniverse-admet-prediction).
中文简介正在准备中。当前显示原文说明。
Drug safety and adverse event analysis — FAERS spontaneous-report mining, FDA black-box warnings, signal detection (PRR, ROR, IC), risk factors by demographic/comorbidity, and label change tracking. Use for post-market safety surveillance, AE signal investigation, drug-AE association strength scoring, and pharmacovigilance reports.
中文简介正在准备中。当前显示原文说明。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
中文简介正在准备中。当前显示原文说明。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
中文简介正在准备中。当前显示原文说明。
在地名、地址与坐标之间转换，搜索周边设施，查询驾车、步行和骑行路线及耗时，也可查看当地时区与时间，用于旅行出行规划和指定区域的设施调查。